First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by ...

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...